SG11202002563WA - Long-acting conjugates of glp-2 derivatives - Google Patents
Long-acting conjugates of glp-2 derivativesInfo
- Publication number
- SG11202002563WA SG11202002563WA SG11202002563WA SG11202002563WA SG11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA SG 11202002563W A SG11202002563W A SG 11202002563WA
- Authority
- SG
- Singapore
- Prior art keywords
- glp
- derivatives
- long
- acting conjugates
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126577 | 2017-09-28 | ||
| PCT/KR2018/011586 WO2019066586A1 (ko) | 2017-09-28 | 2018-09-28 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002563WA true SG11202002563WA (en) | 2020-04-29 |
Family
ID=65902619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002563WA SG11202002563WA (en) | 2017-09-28 | 2018-09-28 | Long-acting conjugates of glp-2 derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11530249B2 (ru) |
| EP (1) | EP3689898A4 (ru) |
| JP (2) | JP2020534840A (ru) |
| KR (2) | KR20190037181A (ru) |
| CN (1) | CN111433221A (ru) |
| AR (1) | AR113258A1 (ru) |
| AU (1) | AU2018339210B2 (ru) |
| BR (1) | BR112020006189A2 (ru) |
| CA (1) | CA3084326A1 (ru) |
| EA (1) | EA202090571A1 (ru) |
| IL (1) | IL273528A (ru) |
| MX (1) | MX2020004453A (ru) |
| PH (1) | PH12020550105A1 (ru) |
| SG (1) | SG11202002563WA (ru) |
| TW (2) | TWI795443B (ru) |
| WO (1) | WO2019066586A1 (ru) |
| ZA (1) | ZA202001888B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021133087A1 (ko) | 2019-12-24 | 2021-07-01 | 한미약품 주식회사 | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 |
| EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| CN115697375A (zh) * | 2020-04-03 | 2023-02-03 | 韩美药品株式会社 | 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物 |
| CA3179472A1 (en) | 2020-05-22 | 2021-11-25 | Sung Hee Hong | Liquid formulation of long-acting conjugate of glp-2 |
| JP2023529478A (ja) | 2020-06-09 | 2023-07-10 | ベクティブバイオ エージー | アプラグルチドの製造、配合、及び投薬 |
| KR20220092446A (ko) | 2020-12-24 | 2022-07-01 | 한미약품 주식회사 | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 |
| KR20230149258A (ko) * | 2022-04-18 | 2023-10-26 | 한미약품 주식회사 | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| AU2002233089B2 (en) * | 2001-02-16 | 2005-12-22 | Conjuchem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders |
| US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| DK1745078T3 (da) * | 2004-04-23 | 2009-10-26 | Conjuchem Biotechnologies Inc | Fremgangsmåde til oprensning af albuminkonjugater |
| BRPI0610091B1 (pt) * | 2005-05-04 | 2021-08-03 | Zealand Pharma A/S | Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2337585A1 (en) * | 2008-09-19 | 2011-06-29 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
| US20160137711A1 (en) * | 2011-09-12 | 2016-05-19 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
-
2018
- 2018-09-28 MX MX2020004453A patent/MX2020004453A/es unknown
- 2018-09-28 TW TW107134398A patent/TWI795443B/zh active
- 2018-09-28 AU AU2018339210A patent/AU2018339210B2/en active Active
- 2018-09-28 TW TW110126453A patent/TWI794897B/zh active
- 2018-09-28 CN CN201880074180.4A patent/CN111433221A/zh active Pending
- 2018-09-28 KR KR1020180116327A patent/KR20190037181A/ko active Application Filing
- 2018-09-28 BR BR112020006189-1A patent/BR112020006189A2/pt unknown
- 2018-09-28 WO PCT/KR2018/011586 patent/WO2019066586A1/ko active Application Filing
- 2018-09-28 AR ARP180102806A patent/AR113258A1/es unknown
- 2018-09-28 CA CA3084326A patent/CA3084326A1/en active Pending
- 2018-09-28 JP JP2020517828A patent/JP2020534840A/ja active Pending
- 2018-09-28 EA EA202090571A patent/EA202090571A1/ru unknown
- 2018-09-28 EP EP18860379.9A patent/EP3689898A4/en active Pending
- 2018-09-28 SG SG11202002563WA patent/SG11202002563WA/en unknown
-
2020
- 2020-03-19 PH PH12020550105A patent/PH12020550105A1/en unknown
- 2020-03-23 IL IL273528A patent/IL273528A/en unknown
- 2020-03-24 ZA ZA2020/01888A patent/ZA202001888B/en unknown
- 2020-03-27 US US16/832,634 patent/US11530249B2/en active Active
-
2022
- 2022-04-14 US US17/721,048 patent/US20220251164A1/en active Pending
- 2022-11-02 US US17/979,531 patent/US20230090790A1/en active Pending
-
2023
- 2023-07-06 JP JP2023111438A patent/JP2023138505A/ja active Pending
-
2024
- 2024-01-22 KR KR1020240009740A patent/KR20240013836A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3689898A1 (en) | 2020-08-05 |
| WO2019066586A1 (ko) | 2019-04-04 |
| MX2020004453A (es) | 2020-07-24 |
| BR112020006189A2 (pt) | 2020-10-13 |
| JP2020534840A (ja) | 2020-12-03 |
| TW201927806A (zh) | 2019-07-16 |
| AR113258A1 (es) | 2020-03-11 |
| US20200262888A1 (en) | 2020-08-20 |
| CN111433221A (zh) | 2020-07-17 |
| EP3689898A4 (en) | 2021-06-16 |
| KR20240013836A (ko) | 2024-01-30 |
| CA3084326A1 (en) | 2019-04-04 |
| ZA202001888B (en) | 2021-05-26 |
| PH12020550105A1 (en) | 2020-12-07 |
| TWI795443B (zh) | 2023-03-11 |
| TWI794897B (zh) | 2023-03-01 |
| KR20190037181A (ko) | 2019-04-05 |
| AU2018339210B2 (en) | 2023-02-02 |
| AU2018339210A1 (en) | 2020-04-16 |
| US20230090790A1 (en) | 2023-03-23 |
| US20220251164A1 (en) | 2022-08-11 |
| JP2023138505A (ja) | 2023-10-02 |
| US11530249B2 (en) | 2022-12-20 |
| EA202090571A1 (ru) | 2020-07-30 |
| IL273528A (en) | 2020-05-31 |
| TW202142560A (zh) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291291A (en) | A glucagon derivative and a preparation containing its long-term active conjugate | |
| SI3592393T1 (sl) | Sprostljivi konjugati | |
| IL273528A (en) | Long-term conjugates of GLP-2 derivatives | |
| ZA201607385B (en) | Anti-ptk7 antibody-drug conjugates | |
| IL248221A0 (en) | Antibody-drug conjugates with high drug loading | |
| ZA201700306B (en) | Her2 antibody-drug conjugates | |
| EP3204018A4 (en) | Neoadjuvant use of antibody-drug conjugates | |
| ZA201707475B (en) | Compositions comprising antibody-duocarmycin drug conjugates | |
| GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| ZA202000215B (en) | Long-acting formulations | |
| HK1257352A1 (zh) | 靶向gcc的抗體-藥物綴合物 | |
| EP3538098A4 (en) | ANTIBODY-ACTIVE SUBSTANCE CONJUGATES | |
| EP3463424A4 (en) | Glucagon-Like Peptide-1 T3 CONJUGATES | |
| GB201706466D0 (en) | pyrrolobenzodiazepine-peptide conjugates | |
| GB201702029D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201418984D0 (en) | Novel drug conjugates |